Drug · DIN 02322285
SOLIRIS
300 MG/30 ML SINGLE-USE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 16, 2013; first marketed May 25, 2009.
- Drug Identification Number (DIN)
- 02322285
- Company (DIN owner)
- Alexion Pharma GmbhBaar, --, Switzerland
- Schedule
- Prescription; Schedule d
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Eculizumab L04AJ01
- Class
- Human
- Record last updated
- August 12, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ECULIZUMAB | 10 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- April 20, 2015: NOC 16813Supplement to a New Drug Submission (SNDS) · Additional drug substance and drug product manufacturing sites
- May 31, 2013: NOC 14414New Drug Submission (NDS) · Administrative - manufacturer name change
- January 28, 2009: NOC 10013New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “soliris”. A notice may cover another product or only some lots: read it to see what it covers.
- SOLIRIS (eculizumab) - Increased Risk of Hemolysis or Low Hemoglobin with Serogroup B Meningococcal VaccinationOctober 25, 2016 · Biologic or vaccine · Product safety
- Soliris (2014-06-06)July 11, 2014 · Drugs · Product safety · Type II